Reddit: Business Resilience Undervalued, Healthy Consolidation Creates A Buying Opportunity — Positive
RDDT Seeking Alpha — November 19, 2025Reddit proved business resilience supported by strong execution capability. Advertising revenue and ARPU are growing rapidly, with fast EBITDA margin improving toward industry-leading levels. Valuation is attractive, with a projected 30% revenue CAGR and strong capital returns justifying a premium, and a target price of $255 is set.
Can CleanSpark's Data Center Push Unlock New AI Revenue Streams? — Positive
CLSK Zacks Investment Research — November 19, 2025CLSK pivots from pure Bitcoin mining to build AI-ready data centers, aiming to unlock long-term growth through diversified digital infrastructure.
Lumen and Meter Launch AI-Driven WAN-to-LAN Solution for Enterprises — Positive
LUMN Zacks Investment Research — November 19, 2025LUMN's collaboration with Meter debuts a unified WAN-to-LAN solution built to simplify AI-ready enterprise connectivity and operations.
Is Percipio the Key to Reshaping Skillsoft's Market Positioning? — Positive
SKIL Zacks Investment Research — November 19, 2025SKIL's Percipio drives soaring AI learning adoption and major workforce wins, strengthening its position in the evolving upskilling market.
Gladstone Capital: The BDC Is Back On The Growth Track, It's A Buy — Positive
GLAD Seeking Alpha — November 19, 2025Gladstone Capital has been one of my equity-focused BDC picks, which as opposed to FDUS and TRIN has delivered unpleasant returns. Recently, GLAD announced a dividend cut, which also came as a surprise to me. Yet, the Q4 2025 data points, in my view, indicate a clear turning point.
Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) — Neutral
LGVN GlobeNewsWire — November 19, 2025MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its submission entitled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study” has been selected for a poster presentation at the 18th Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) to be held December 1-4, 2025 in San Diego, CA. “We are excited to have been selected to present important laromestrocel data at this leading forum for Alzheimer's research and clinical investigation,” said Joshua …
Astrotech Announces Review of Strategic Alternatives to Maximize Shareholder Value — Neutral
ASTC GlobeNewsWire — November 19, 2025AUSTIN, Texas, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) today announced that its Board of Directors has initiated a review of strategic alternatives in order to explore ways to maximize shareholder value. The review will include a range of potential actions, including raising equity capital, reverse mergers, combination transactions, and the sale of all or part of the Company's business, and other possible strategic or financial transactions.
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 — Neutral
RNA PRNewsWire — November 19, 2025SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access Program (MAP) for investigational therapy delpacibart zotadirsen (del-zota) for eligible people with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) in the United States. "We recognize the considerable needs facing the DMD44 community given there are no approved exon skipping therapies for this disease as well as the potential of del-zota based on the unprecedented data shown in our clinical studies," said Sarah …
Nvidia stock price forecast: NVDA is extremely cheap ahead of earnings — Positive
NVDA Invezz — November 19, 2025Nvidia stock price has pulled back in the past two weeks, moving from the year-to-date high of $212 to $180. This retreat will either accelerate or reverse once the company publishes its financial results later today.
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action — Neutral
MLTX Newsfile Corp — November 19, 2025New York, New York--(Newsfile Corp. - November 19, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=178166&wire=5&utm_campaign=12 or contact Joseph E. Levi, Esq.
Actelis Networks Secures New Order for Leading Japanese Railway Operator — Neutral
ASNS GlobeNewsWire — November 19, 2025Nearly $100,000 order demonstrates growing adoption of Actelis' networking solutions in Japan's rail sector Nearly $100,000 order demonstrates growing adoption of Actelis' networking solutions in Japan's rail sector
Rigetti: Quantum Infrastructure Cornerstone In The Making — Positive
RGTI Seeking Alpha — November 19, 2025Rigetti Computing (RGTI) remains a 'Buy' due to its accelerated technology roadmap, commercial wins, and strong strategic positioning in quantum computing. RGTI's modular chiplet architecture and ambitious milestones, including a 1,000+ qubit system by 2027, differentiate it from competitors and add credibility. Recent commercial wins, including contracts with AFRL and partnerships with Nvidia, validate RGTI's technology and expand its growth opportunities.
M2i Global, Volato Group sign MOU with Nimy Resources for access to Western Australia gallium — Positive
MTWO SOAR Proactive Investors — November 19, 2025M2i Global Inc (OTC:MTWO) and Volato Group have signed a memorandum of understanding (MOU) with Nimy Resources to pursue a supply agreement for gallium sourced from Western Australia, the companies announced on Wednesday. Under the non-binding MOU, Nimy and M2i plan to work toward commercially binding terms for the sale and purchase of gallium from Nimy's Mons Project.
WIX's Q3 Earnings & Revenues Top, Increase Y/Y on Base44 Momentum — Positive
WIX Zacks Investment Research — November 19, 2025WIX posts Q3 beat as 14% revenue growth and surging Base44 adoption push the company to raise full-year bookings and revenue guidance.
Valvoline (VVV) Q4 Earnings and Revenues Miss Estimates — Negative
VVV Zacks Investment Research — November 19, 2025Valvoline (VVV) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.46 per share a year ago.
Viking Holdings (VIK) Q3 Earnings and Revenues Top Estimates — Positive
VIK Zacks Investment Research — November 19, 2025Viking Holdings (VIK) came out with quarterly earnings of $1.2 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $0.89 per share a year ago.
Brookfield Corporation to Issue C$200 Million of Preferred Shares and Redeem a Minimum of C$200 Million of its Class A Preference Shares, Series 44 — Neutral
BN GlobeNewsWire — November 19, 2025Not for distribution to U.S. news wire services or dissemination in the United States. THE BASE SHELF PROSPECTUS IS ACCESSIBLE, AND THE SHELF PROSPECTUS SUPPLEMENT FOR THE PUBLIC OFFERING AND ANY AMENDMENT TO THE DOCUMENTS WILL BE ACCESSIBLE, WITHIN TWO BUSINESS DAYS, THROUGH SEDAR+ BROOKFIELD, NEWS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced that it has agreed to issue 8,000,000 Class A Preference Shares, Series 54 (“Preferred Shares, Series 54”) on a bought deal basis to a syndicate of underwriters (the “Underwriters”) led by Scotiabank, BMO Capital Markets, CIBC Capital Markets, National …
Can a single stock take down the whole market? What to know ahead of Nvidia's critical earnings — Neutral
NVDA The Street — November 19, 2025Can a single stock take down the whole market? Here's what to know ahead of Nvidia's critical earnings.
Markets Stumble As Fed Signals, Earnings, And AI Crosscurrents Drive Volatility — Neutral
NVDA Forbes — November 19, 2025Key Takeaways
META Platforms stock (NASDAQ: META) has declined by 18.4% within a span of 21 trading days. This significant drop indicates renewed worries among investors concerning the company's aggressive expenditure on both AI infrastructure and its Reality Labs division.